Xanthostat has developed a product that aids in diagnosing subarachnoid Hemhorrages (SAH). Our product is now ready to submit to the FDA for approvall under the 510(k) process. SAH takes over 30,000 lives annually. The better detection that our medical device provides could greatly reduce the number of misdiagnoses and hence save lives. Our customers are the hospital ER Doctors and Neurosurgeons that handle the SAH cases.